Risk factors
Organon (OGN) risk factors
Item 1A of every Organon & Co. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors47 risks17 new8 dropped19 reworded
Internal investigation over Nexplanon sales practices and material weaknesses in financial controls dominate the new disclosures. Capital allocation priority shifted to deleveraging $8.6 billion in debt, resulting in a 90% dividend cut. Goodwill impairment of $301 million recorded for the U.S. reporting unit due to lower-than-expected financial performance.
Filed Feb 24, 2026 - FY2024 10-K risk factors38 risks
Organon relies heavily on key products like Nexplanon and Singulair, generating 75 percent of its 6.4 billion dollar revenue outside the US.
Filed Feb 28, 2025